CDI
OpenBiome No Longer Distributing FMT For Recurrent C. difficile Infections
OpenBiome has voluntarily suspended distribution of fecal transplantation preparations for the treatment of ...
DECEMBER 13, 2024
How Have FDA Approvals Changed the Landscape of Microbiome Therapeutics?
At DDW 2024, Jessica Allegretti, MD, MPH, described new treatments for recurrent C. difficile and how she ...
AUGUST 19, 2024
The Time Is Right to Study Microbiome in IBD Therapy
Fecal microbiota transplants that alter the gut microbiome could bring relief to people with IBD who do not respond ...
JUNE 18, 2024
C. diff Update: Tips to Treat a Stubborn Infection
Managing Clostridioides difficile infection is a challenge that requires a multipronged approach.
APRIL 19, 2024
Gut Microbiome Updates From ACG 2023
The microbiome topics at ACG 2023 covered almost every organ system and did not disappoint with interesting ...
JANUARY 14, 2024
2 Steps Are Better Than 1 for CDI Testing
A two-step algorithm for Clostridioides difficile infection testing may reduce unnecessary treatment and improve ...
JUNE 12, 2023
FDA Approves First Orally Administered Fecal Microbiota Product to Prevent C. diff Recurrence
The FDA approved the first fecal microbiota product that is taken orally to prevent recurrent CDI in people who are ...
APRIL 28, 2023
Expert Picks From ACG 2022, Part 1
In part 1 of a two-part series, Brooks Cash, MD, discusses what he considers some of the research highlights from ...
JANUARY 10, 2023
FDA Approves Rebyota, the First Live Biotherapeutic Fecal Microbiota Product in the U.S.
RBX2660 (Rebyota, Ferring) is approved by the FDA for the prevention of recurrent Clostridioides difficile ...
DECEMBER 5, 2022
Recently Hospitalized Patients Increase Risk for Household Transmission of CDI
Exposure to recently hospitalized family members significantly increased the risk for developing C. difficile ...
JUNE 2, 2022
Increased C. difficile Risk for Patients in Rooms Previously Occupied by CDI-Infected Patients
A hospitalized patient whose room was previously occupied by someone with CDI is 27% more likely to become infected ...
MAY 27, 2022
CDI Risk Increases With 5-ASA in Pediatric IBD Patients
The use of 5-aminosalicylic acid significantly increases the risk for Clostridioides difficile infection in ...
MARCH 23, 2022
